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Abstract:  Osteoporosis  is  the  index  disease  for  calcium  deficiency,  just  as 
rickets/osteomalacia is the index disease for vitamin D deficiency, but there is considerable 
overlap between them. The common explanation for this overlap is that hypovitaminosis D 
causes malabsorption of calcium which then causes secondary hyperparathyroidism and is 
effectively  the  same  thing  as  calcium  deficiency.  This  paradigm  is  incorrect. 
Hypovitaminosis D causes secondary hyperparathyroidism at serum calcidiol levels lower 
than 60 nmol/L long before it causes malabsorption of calcium because serum calcitriol 
(which  controls  calcium  absorption)  is  maintained  until  serum  calcidiol  falls  below  
20 nmol/L. This secondary hyperparathyroidism, probably due to loss of a ―calcaemic‖ 
action  of  vitamin  D  on  bone  first  described  in  1957,  destroys  bone  and  explains  why 
vitamin D insufficiency is a risk factor for osteoporosis. Vitamin D thus plays a central role 
in  the  maintenance  of  the  serum  (ionised)  calcium,  which  is  more  important  to  the 
organism than the preservation of the skeleton. Bone is sacrificed when absorbed dietary 
calcium  does  not  match  excretion  through  the  skin,  kidneys  and  bowel  which  is  why 
calcium  deficiency  causes  osteoporosis  in  experimental  animals  and,  by  implication, 
in humans.  
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1. Instruction  
According  to  current  knowledge,  cholecalciferol  (vitamin  D3)  is  synthesised  in  the  skin  from  
7-dehydrocholesterol  under  the  influence  of  sunlight,  conveyed  to  the  liver  to  be  converted  into  
25-hydroxy cholecalciferol (calcidiol) which is conveyed to be kidneys for further conversion into  
1,25-dihydroxy-cholecalciferol (calcitriol) or downgraded to 24,25-dihydroxycholecalciferol. Calcidiol 
circulates  in  plasma  in  nanomolar  concentrations,  mostly  bound  to  D-binding  protein  (DBP),  and 
calcitriol in picommolar concentrations, also largely bound to DBP. However, because the vitamin D 
receptor has a much higher affinity for calcitriol than for calcidiol, the former has much the more 
powerful action on calcium absorption and bone resorption than the latter and is frequently referred to 
as  the  ―active  metabolite‖  of  vitamin  D  or  the  ―hormonal  form‖.  It  should  be  noted  that  the 
hypercalcaemia of vitamin D over-dosage is probably more due to high bone resorption than to high 
calcium absorption. 
The index disease for vitamin D deficiency is rickets in children and osteomalacia in adults, just as 
the index disease for calcium deficiency is osteoporosis [1]. But there is some overlap between these 
two deficiency-states. The explanation for both the difference and the overlap between them is not well 
understood by many workers in the field who appear to be operating in an outdated paradigm. This is 
best understood by looking at the history of the subject which was reviewed by Nordin in 1960 [2] but 
now tends to be overlooked.  
Briefly, the disease of rickets/osteomalacia, first described in the 17th century, became rampant in 
industrialised countries during the 19th century but was not clearly distinguished from osteoporosis 
until 1885 [3] when Pommer showed that it was not due to removal of calcium from bone but failure to 
deposit calcium in new bone. It was already known to be associated with lack of sunlight and to be 
curable with fish oils but was generally also thought to be a form of calcium deficiency until the 
distinction between calcium deficiency, causing osteoporosis, and sunlight deficiency, causing rickets, 
was clearly established in the early twentieth century by German researchers [4]. The active principle 
in fish oils was later identified as vitamin D by Mellanby in 1919 [5]. For a brief period, the distinction 
between calcium deficiency and vitamin D deficiency was the accepted paradigm but when it was 
shown in the 1920’s that rickets was associated with malabsorption of calcium [6], it came to be 
thought  that  malabsorption  of  calcium  was  the  cause  of  the  disease  and  the  pathogenesis  of 
osteoporosis  was  returned  to  limbo.  At  this  point,  Fuller  Albright  introduced  the  idea  that 
rickets/osteomalacia could be due to deficiency of vitamin D or calcium and declared that osteoporosis 
was due to a failure of osteoblasts to lay down new bone [7]. He brilliantly predicted and explained the 
adverse  effect  on  bone  formation  of  what  he  called  the  S-hormone  (Sugar-hormone),  which  later 
proved to be hydrocortisone, but he was wrong in extending this concept to postmenopausal bone loss 
which is due to an increase in bone resorption. In fact, when bone formation rate became measurable 
with radiocalcium it was shown to be no lower in osteoporotic than normal women but such was his 
influence that his paradigm still carries considerable weight. Yet a seminal Swedish paper in 1955 [8] 
showed that vitamin D did more than simply regulate calcium absorption—it also had an independent 
calcaemic action which helped to maintain plasma calcium in a manner that could not be attributed to 
its action on calcium absorption; this work explained the difference between calcium deficiency and 
vitamin D deficiency shown 50 years earlier in Germany. It is now clear that negative calcium balance, Nutrients 2010, 2  
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whether due to low intake, low absorption or high excretion of calcium, causes osteoporosis because 
the  maintenance  of  the  plasma  calcium  concentration  is  more  important  to  the  organism,  for 
neuromuscular and other reasons, than is the preservation of the skeleton; the calcium deficit is made 
up by breaking down bone rather than by lowering the calcium concentration in the tissue fluids. The 
role of parathyroid hormone in this process is still the subject of controversy but the sequence of 
events from hypovitaminosis D to rickets/osteomalacia as already understood in the 1960’s remains 
valid today. Because of the loss of its calcaemic action (the precise mechanism of which is not fully 
understood),  lack  of  vitamin  D  causes  a  fall  in  the  calcium  level  in  the  tissue  fluids,  secondary 
hyperparathyroidism and hypophosphataemia, to which malabsorption of phosphate also contributes. 
This hypophosphataemia lowers the tissue fluid Ca ×  P product which delays the mineralisation of new 
bone and calcification of growth cartilage which are the essential features of osteomalacia and rickets.  
The reason for the overlap between the two conditions is also now apparent in that the secondary 
hyperparathyroidism which appears early in vitamin D insufficiency increases bone resorption and so 
accelerates the osteoporotic process but at the same time maintains the serum calcitriol (and therefore 
calcium  absorption)  until  the  D-deficiency  is  so  severe  that  the  calcitriol  level  falls  from  lack  of 
substrate  which  leads  to  the  malabsorption  of  calcium  and  phosphate  which  are  a  feature  of 
rickets/osteomalacia [9]. Every degree of vitamin D insufficiency can be seen in the histology [10] and 
serum  biochemistry  [11,12]  of  hip  fracture  patients  who  generally  suffer  from  malabsorption  of 
calcium  [13]  due  to  varying  combinations  of  low  serum  calcitriol  and  age-related  ―resistance‖  to 
calcitriol (see below). Conversely, in young animals with a high calcium requirement for growth, it is 
possible for severe calcium deficiency to cause hypocalcaemia and consequent rickets/osteomalacia 
even  when  vitamin  D  status  is  normal  [14].  Thus  the  overlap  between  calcium  and  vitamin  D 
deficiency can be explained in both directions.  
This ―new‖ paradigm, first described in 1960 [2], is heavily dependent on a knowledge of the 
internal relationships between serum PTH, calcidiol, calcitriol and calcium absorption, all of which 
can be measured. The only one of these measurements that is at all controversial is that of calcium 
absorption  which  used  to  be  determined  by  balance  procedures  which  are  now  considered  too 
expensive and time-consuming even for research purposes and quite out of the question for routine 
use.  Calcium  balance  studies  have  therefore  been  largely  superseded  by  a  simple  radiocalcium 
procedure pioneered by Avioli [15] but revised, developed and applied over the last forty years by 
Nordin and colleagues, first in Leeds, England and then in Adelaide, Australia. The theoretical basis of 
this procedure was first set out in 1969 [16] and based on the administration of radiolabelled calcium 
in 20 mg of calcium carrier to the fasting subject, collection of 6 blood samples over the next 2 hours 
and calculation of the rates of calcium input and output by deconvolution analysis. The radiocalcium 
absorption calculated in this way was shown to correlate very significantly with the rate of dietary 
calcium absorption (corrected for intake) in simultaneous calcium balances [17] and very highly with 
calcium absorption calculated by the double isotope method [18]. The results were shown to fall with 
age [19], to be high in hyperparathyroidism and calcium-stone disease and low in osteomalacia and 
renal failure [17], and (as said above) low in women with hip fractures [13]. Radiocalcium absorption 
was  later  shown  to  rise  on  treatment  of  osteoporosis  [20]  and  renal  failure  [21]  with  
1-hydroxyvitamin D and to be related to the serum calcitriol level [22,23].  Nutrients 2010, 2  
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Further experience showed that the plasma radioactivity 60 minutes after the tracer dose (the peak 
value) was so highly correlated with the absorption rate calculated from the 6 blood samples (r values 
around 0.9) [18], that this single blood sample was adopted as a valid basis for calculating calcium 
absorption as an hourly fractional rate from a conversion equation [24] which was later further refined 
to correct for body weight [25]. This simplified test has since been shown to behave in the same way 
as the full procedure; it correlates in the same way with the serum calcitriol and responds in the same 
way to calcitriol therapy [26-28]. It has demonstrated that the fall in calcium absorption with age 
cannot be accounted for by a fall in serum calcitriol [29] as has also been reported in aged rats [30]. A 
longitudinal  study  across  the  menopause  also  showed  a  fall  in  calcium  absorption  at  menopause 
independent of serum calcitriol [31] as had previously been shown in ovariectomised rats [32]. The 
practical clinical significance of this test is shown by the fact that calcium supplementation is much 
more effective in suppressing bone turnover markers in women with normal radiocalcium absorption 
than in those with low radiocalcium absorption [33]. 
It needs to be emphasised that the small amount of calcium carrier used in this absorption test is 
crucial to its validity. The low carrier ensures that absorption occurs quickly and over a limited length 
of small intestine which yields the clean curve that would be expected from absorption at a single point 
and which is analysable on that assumption. The more carrier that is used, the lower the fraction 
absorbed, the longer the length of small intestine involved and the less analysable the subsequent curve 
becomes since it is in fact a family of curves. The use of 250 mg or more of calcium carrier is 
superficially attractive because that represents a normal meal but it cannot be done with a single 
isotope—it  requires  a  double  isotope  procedure.  Moreover,  the  high  carrier  version  of  the  single 
isotope test [34] is not only insensitive but must carry a large error and has never been shown to 
correlate with serum calcitriol or validated in the same way as the low carrier test. What an absorption 
test should provide is reliable information about the active transport component of calcium absorption. 
The  assumption,  borne  out  by  combined  isotope  and  balance  studies  [25],  is  that  it  reflects  the 
―normality‖ of calcium absorption at all intakes. Net absorbed calcium can be corrected for intake by 
calculation from calcium balance studies on normal subjects and is largely mediated by a saturable 
transport process [17] and correlated with radiocalcium absorption. Thus a radiocalcium absorption 
rate of 0.75 per hour—the normal mean [31]—signifies that absorption is probably normal for intake at 
all  physiological  intakes.  The  test  is  not  a  measure  of  serum  calcitriol  as  such  but  of  calcium 
absorptive status. The main determinant of calcium absorption is of course the serum calcitriol level 
but ageing and menopause are both associated with a ―resistance‖ to calcitriol and this is particularly 
true in osteoporotic women with vertebral fractures [35]. Despite this, the calcium malabsorption in 
such patients can be corrected by calcitriol administration and there is a dose-response relationship 
between the dose of calcitriol and the radiocalcium absorption level which is established within a few 
days  [36]  whereas  Vitamin  D  alone  has  little  or  no  effect on calcium absorption in  women  with 
vertebral fractures [37]. It may be possible to show a weak positive univariate correlation between 
calcium absorption and serum calcidiol due to the internal correlation between serum calcidiol and 
calcitriol, generally about 0.3 (P < 0.001), which is simply because the former is the substrate for the 
latter; when serum calcitriol is included in the equation, serum calcidiol invariably drops out. It is most 
unfortunate  that  this  spurious  correlation  between  calcidiol  and  calcium  absorption  [38]  has  been 
accepted so easily by some sections of the scientific community when it is not only incorrect but offers Nutrients 2010, 2  
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a misleading explanation of the secondary hyperparathyroidism which is such an important feature of 
hypovitaminosis D. 
As far as vitamin D requirement is concerned, with a half-life of about 20 days, the serum calcidiol 
will sooner or later reach an equilibrium value on any particular dose of vitamin D sooner or later, as 
elegantly shown by Stamp many years ago [39]. The rise depends largely on the starting value. The 
vitamin D requirement must be the amount required to achieve a desirable equilibrium value. We 
regard the intervention value as 60 nmol/L (because that is the value below which bone turnover 
markers to rise [40]) and the desirable level as 80–100 nmol/L. The latter can be achieved in a matter 
of weeks in most subjects on a dose of 1,000 units daily of cholelcalciferol but we are aware of the 
view that the optimal level should perhaps be higher, and it is possible that 2,000 units a day will 
ultimately come to be regarded as the correct standard dose, but we see no merit in large loading doses 
since vitamin D-insufficiency can hardly be regarded as an emergency. We regard 25OHD values 
between  15  and  60  nmol/L  as  vitamin  D  ―insufficiency‖  and  values  below  15  nmol/L  as  true 
―deficiency‖ which ultimately leads to rickets/osteomalacia [9]. However, we are satisfied from the 
evidence that prevention of bone loss and fractures in the elderly requires a combination of calcium 
with vitamin D [41-43] and we now believe that the current calcium allowance for postmenopausal 
women of 1,300 mg [44] should probably be 1,500 mg [45]. However, it has to be said that the use of 
calcium balances to calculate calcium requirement is complicated by uncertainty about dermal losses. 
The FAO/WHO Requirements and Allowances [44] assumed a skin loss of 60 mg daily, as reported by 
Charles et al. [46], but Charles has now reported a technical error in his procedure and believes the 
correct figure should be about 30–40 mg [personal communication]. It is therefore important to seek 
further evidence on dermal losses of calcium. On the other hand, Nordin’s review of 32 calcium trials 
in postmenopausal women [47] provides empirical evidence that their average requirement is about 
1,300 mg which suggests that the allowance should in fact be about 1,500 mg. 
2. Conclusions 
It follows from this brief review that the ―new‖ paradigm introduced by Nordin in 1960 [2] fits the 
available facts better than the ―old‖ paradigm which fails to explain the differences and similarities 
between calcium and vitamin D deficiency. Importantly, the widespread but misleading concept that 
malabsorption of calcium per se causes secondary hyperparathyroidism needs to be corrected [28]. 
This confusion of paradigms in the scientific community has allowed the pharmaceutical industry to 
penetrate the market with expensive remedies for the treatment of osteoporosis when the correct policy 
should  surely  be  bone  densitometry  of  all  women  at  menopause  and  the  adoption  of  appropriate 
lifestyle measures by those with ―osteopenia‖ [48] to prevent them developing osteoporosis. 
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